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Abstract
Introduction: Chondroitin sulfate (CS) is a symptomatic slow-acting drug for osteoarthritis (OA) widely used in the
clinic. The aim of this work is to find proteins whose secretion from cartilage cells under proinflammatory stimuli
(IL-1b) is regulated by CS, employing a novel quantitative proteomic approach.
Methods: Human articular chondrocytes released from three normal cartilages were grown in SILAC medium. When
complete incorporation of the heavy isotope was achieved, chondrocytes were stimulated with IL-1b 5 ng/ml with or
without CS pretreatment (200 µg/ml). Forty-eight hours later, chondrocyte secretomes were analyzed by nano-scale
liquid chromatography-mass spectrometry. Real-time PCR, western blot and immunohistochemistry analyses were
employed to confirm some of the results.
Results: We could identify 75 different proteins in the secretome of human articular chondrocytes. Eighteen of
these were modulated by CS with statistical significance (six increased and 12 decreased). In normal chondrocytes
stimulated with IL-1b, CS reduces inflammation directly by decreasing the presence of several complement
components (CFAB, C1S, CO3, and C1R) and also indirectly by increasing proteins such as TNFa-induced protein
(TSG6). TSG6 overexpression correlates with a decrease in pro-matrix metalloproteinase activation (observed in
MMP1 and MMP3 levels). Finally, we observed a strong CS-dependent increase of an angiogenesis inhibitor,
thrombospondin-1.
Conclusion: We have generated a quantitative profile of chondrocyte extracellular protein changes driven by CS in
the presence of IL-1b. We have also provided novel evidences of its anti-angiogenic, anti-inflammatory, and anti-
catabolic properties. Demonstration of the anti-angiogenic action of CS might provide a novel therapeutic
approach for OA targeting.
Introduction
Osteoarthritis (OA) is one of the most prevalent chronic
diseases affecting older people. Although its major fea-
ture is the progressive destruction of articular cartilage, it
is now accepted that OA is a global disease of the joint,
also involving the synovial membrane, subchondral bone
and periarticular soft tissues [1]. Effective prevention of
the structural damage must be a key objective of new
therapeutic approaches to treat OA. However, drugs
currently available are predominantly directed towards
the symptomatic relief of pain and inflammation, doing
little to reduce joint destruction [2].
Until now the pharmacological management of OA has
been dominated by nonsteroidal anti-inflammatory drugs
and analgesics (mainly paracetamol). However, the use of
chondroitin sulfate (CS) by OA patients, alone or in com-
bination with glucosamine sulfate (GS), has been rising
globally over the last decade. Both molecules are well
recognized as symptomatic slow-acting drugs for OA.
Moreover, their application has an excellent safety pro-
file, allowing long-term treatment [3-6]. Nevertheless,
recent meta-analysis [7] and large-scale clinical trials [8]
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have demonstrated variable effects on OA symptoms,
yielding conflicting results. For this reason, in 2010 we
carried out the first pharmacoproteomic analysis of
articular chondrocytes treated with exogenous CS and/or
GS [9] with the aim of defining more clearly the effects
of GS and CS on cartilage biology. In that work, we per-
formed a classical proteomic approach by two-dimen-
sional electrophoresis and mass spectrometry (MS) to
describe the cellular proteome of normal human chon-
drocytes treated with both drugs, alone or in combina-
tion, in the presence of IL-1b, a proinflammatory
cytokine that plays a pivotal role in the pathogenesis of
OA [10]. A large number of target proteins of CS and GS
were described, pointing out the wide range effects of
these drugs on fundamental aspects of chondrocyte
metabolism but also their alternative mechanisms of
action in a system model of OA [9].
Once the utility of proteomics for analyzing the putative
intracellular targets of CS and GS in cartilage cells was
proved [9], we focused on the subset of chondrocyte extra-
cellular proteins that are essential for cartilage extracellular
matrix (ECM) synthesis and turnover processes. Further-
more, secreted proteins may end up in the bloodstream,
and thereby may have potential use as non-invasive
biomarkers [11]. For these reasons, the chondrocyte secre-
tome has emerged as an attractive starting point for the
discovery of new OA drug targets, for the monitoring of
clinical trials or for the personalization and optimization of
long-term therapies. We recently published the first quan-
titative study of the secretome of primary human articular
chondrocytes (HACs) by chondrocyte metabolic labeling,
using an in vitro model of inflammation by stimulation
with IL-1b [12]. In the present work, we aimed to employ
this model to generate a quantitative profile of chondrocyte
extracellular protein changes driven by CS in the presence
of the proinflammatory stimulus, which might provide
novel molecular evidence for CS effects.
Materials and methods
Cartilage procurement and processing
Macroscopically normal human knee cartilage from three
adult donors (70, 73 and 78 years old) with no history of
joint disease was provided by the Tissue Bank and the
Autopsy Service at CHU A Coruña for the proteomic ana-
lysis. The study was approved by the local ethics commit-
tee. Cartilage was processed as previously described [13].
Primary culture of chondrocytes
HACs were isolated as described previously [9,13]. Briefly,
cartilage surfaces were rinsed with saline buffer, and scal-
pels were used to cut parallel vertical sections 5 mm apart
from the cartilage surface to the subchondral bone. These
cartilage strips were dissected from the bone, and the tis-
sue was incubated with trypsin at 37°C for 10 minutes and
then digested with type IV clostridial collagenase. The
release of chondrocytes from cartilage was achieved after
16 hours of digestion in an incubator at 37ºC, 5% carbon
dioxide.
Chondrocyte metabolic labeling and differential
treatment of SILAC cell populations
The isolated chondrocytes were recovered and plated at
low density in SILAC DMEM-Flex (Invitrogen, Paisley,
UK) deficient in arginine (R) and lysine (K) supplemen-
ted with 10% dialyzed fetal bovine serum (Gibco, Invi-
trogen), 4.5 g/l glucose (Sigma, St. Louis, MO, USA),
2 mM L-glutamine (Sigma), 100 units/ml penicillin and
100 µg/ml streptomycin. In the case of light media,
standard L-lysine and L-arginine were used, while in the
heavy media, isotope-labeled L-lysine (13C6) and iso-
tope-labeled L-arginine (13C6,
15N4) were used. For the
initial cell expansion, 5×104 chondrocytes from each
donor were seeded in two T-25 cell culture flasks (one
grown in light medium and one in heavy medium). At
confluence cells were recovered from each culture flask
by trypsinization and seeded onto two six-multiwell
plates (15×104 for well) for cell treatment. Chondrocytes
were used at week 3 in primary culture, when 100% of
labeling was reached. Verification of complete labeling
was performed as previously described [12]. Briefly, a
small aliquot of cells cultured in the heavy media were
subjected to protein extraction. The extracts were then
digested with trypsin and analyzed by nano-scale liquid
chromatography (LC)-MS to determine the degree of
incorporation by looking for the presence of light pep-
tides. Verification of cell type was carried out by real-
time PCR for the analysis of type II collagen mRNA
expression under the conditions of study.
The chondroitin sulfate employed in this work is of
bovine origin, with a CS content of 99.9% and a molecular
weight of 15.12 kDa. Other characteristics (viscosity, sulfa-
tion sites, and so forth) have been previously detailed else-
where [14]. Chondrocyte stimulation for the experiments
was carried out following procedures previously described
by our group, in which CS and IL-1b concentrations in
the chondrocyte cultures were optimized for the proteo-
mic studies [9,12]. Briefly, cells were washed thoroughly to
remove abundant serum proteins and were cultured in
serum-free medium with or without chondroitin sulfate
(200 μg/ml; Bioibérica, Barcelona, Spain). Two hours later,
IL-1b was added to the culture media (5 ng/ml; Sigma).
Finally, conditioned media were collected after 48 hours of
culture. Cell viability was assessed by Trypan Blue dye
exclusion.
Processing of conditioned media for analysis by LC-MS
Conditioned media obtained from three different donors
were analyzed independently. In addition, the off-gel
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measurements were performed in duplicate to assess the
technical reproducibility of the LC-MS set-up.
Conditioned media were collected, centrifuged and fil-
tered using a 0.2 µm filter to ensure removal of any dead
cells. Proteins in the individual medium were precipitated
with 0.02% sodium deoxycholate for 10 minutes and then
with 10% (v/v) trichloroacetic acid overnight at 4ºC. Pre-
cipitates were harvested by centrifugation at 13,000 rpm
for 15 minutes at 4°C and then washed twice with ice-
cold acetone. The protein pellets were dried in air and
then resuspended in 6 M urea, 2 M thiourea and 25 mM
ammonium bicarbonate. The protein content of the con-
centrated media was measured using the Bradford
reagent from Sigma. Heavy and light samples were then
mixed 1:1, and 4 μg of each mixed sample were in-solu-
tion reduced, alkylated and digested with trypsin. Diges-
tion was performed overnight with 12.5 ng/l Sequencing
Grade Modified Trypsin (Promega, Madison, WI, USA)
at 37ºC. The mixtures were acidified with Trifluoroacetic
acid (1% final concentration) to stop the enzymatic reac-
tion. The resulted peptides were desalted and filtered
through a C18 microcolumn (NuTip; Glygen, Columbia,
MD, USA) and finally eluted from the C18 bed using
70% Acetonitrile/0.1% TFA. The organic component was
removed by evaporating in a vacuum centrifuge and the
peptides were resuspended in 2% Acetonitrile/0.1% TFA.
Then 5 µl were injected into a reversed-phase column
(Integrafit C18, Proteopep™ II; New Objective, Woburn,
MA, USA) for nano-flow LC analysis, using a Tempo
nanoLC (Eksigent, Dublin, CA, USA) equipped with a
Sun Collect MALDI Spotter/Micro-Fraction Collector
(SunChrom GmbH, Friedrichsdorf, Germany).
Nano-scale LC-MALDI-MS analysis
LC eluate was deposited onto an Opti-TOF LC MALDI
target plate (1,534-spot format; ABSciex, Framingham,
MA, USA) with a speed of one spot per 15 seconds. Before
spotting, the LC microfractions were mixed with MALDI
matrix (3 mg/ml a-cyano-4-hydroxycinnamic acid in 70%
Acetonitrile and 0.1% TFA containing 10 fmol/μl angio-
tensin as internal standard). Peptide-containing LC spots
were analyzed in a 4800 MALDI-TOF/TOF instrument
(ABSciex) with a 200 Hz repetition rate (Nd:YAG laser).
MS full-scan spectra were acquired from 800 to 4,000 m/z.
A total of 1,500 laser shots were accumulated for each
time-of-flight MS spectrum at an optimized fixed laser set-
ting. Tandem MS mode was operated with 1 kV collision
energy with CID gas (air) over a range of 60 to -20 m/z of
the precursor mass value. The precursor mass window
was 300 ppm (full width at half-maximum) in relative
mode. A minimum of 800 and a maximum of 1,500 laser
shots were accumulated with laser stop conditions set at
10 product ion peaks of signal-to-noise ratio >100 at an
optimized, fixed laser setting with metastable suppressor
option on. Data-dependent tandem MS settings included
acquisition of up to 20 of the most intense ion signals per
spot. If two or more consecutive spots in an LC run with
precursor m/z were within 200 ppm tolerance, the spot
with the maximum signal-to-noise ratio was subjected to
tandem MS analysis.
Data analysis
Peptide and protein identification and comparative quan-
tification were performed using the Protein Pilot software
vs 3.0 (ABSciex) with Paragon Algorithm. MS/MS data
was searched against the UniProt/Swiss-Prot database of
protein sequences (August 2010; Swiss-Prot, Geneva,
Switzerland), using the following parameters: sample type
set as SILAC (Lis+6, Arg+10), cysteine alkylation with
Iodoacetamide, urea denaturation, one missed cleavage
allowed in trypsin digestion and focus in biological modi-
fications. Only proteins with a threshold >95% confi-
dence (>1.3 unused score) were considered for protein
identification. Data were normalized for mixing error by
bias corrections.
Real-time PCR assays
Total RNA was isolated from chondrocytes (5×105 per
well) using Trizol Reagent (Invitrogen, Carlsbad, CA,
USA), following the manufacturer’s instructions. cDNA
was synthesized from 1 μg total RNA, using the Transcrip-
tor First Strand cDNA Synthesis Kit (Roche Applied
Science, Mannheim, Germany) in accordance with the
manufacturer’s instructions, and was analyzed by quantita-
tive real-time PCR. The quantitative real-time PCR assay
was performed in the LightCycler 480 instrument (Roche
Applied Science) using 96-well plates. Primers for throm-
bospondin-1 (TSP1), TNFa-induced protein (TSG6) and
the housekeeping genes, HPRT1 and RPLP0, were
designed using the Universal Probe Library tool from the
Roche website [15]. Primer sequences were as follows:
TSP1 forward, 5’-GCTGCACTGAGTGTCACTGTC-3’;
TSP1 reverse, 5’-TCAGGAACTGTGGCATTGG-3’;
TSG6 forward, 5’-GCTAGAGGCAGCCAGAAAAA-3’;
TSG6 reverse, 5’-ATCCAACTCTGCCCTTAGCC-3’;
HPRT1 forward, 5’-TGACCTTGATTTATTTTGCA-
TACC-3’; HPRT1 reverse, 5’-CGAGCAAGACGTT-
CAGTCCT-3’; RPLP0 forward, 5’-TCTACAACCCTGA
AGTGCTTGAT-3’, PRPL0 reverse 5’-CAATCTGCAGA-
CAGACACTGG-3’. The results were analyzed using the
LightCycler 480 software release 1.5.0 (Roche Applied
Science), which automatically recorded the threshold cycle
(Ct). An untreated cell sample (basal) was used as the cali-
brator; the fold-change for this sample was 1.0. Target
gene Ct values were normalized against HPRT1 and
RPLP0. Data were analyzed using the 2-ΔΔCt method and
expressed as the fold-change of the test sample compared
with the basal condition [16].
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Western blot analysis
Western blot analyses were performed utilizing stan-
dard procedures. Briefly, 20 μg secreted proteins and
50 μg intracellular proteins were loaded and resolved
using 10% SDS-PAGE. The separated proteins were
then transferred to polyvinylidene fluoride membranes
(Immobilon P; Millipore Co., Bedford, MA, USA) by
electroblotting and probed with specific antibodies
against TSP1 (Santa Cruz Biotechnology, Santa Cruz,
CA), TSG6 (Abnova, Taipei, Taiwan), MMP1 and
MMP3 (Abcam, Cambridge, UK). Immunoreactive
bands were detected and housekeeping control
GAPDH (Sigma). Immunoreactive bands were detected
by chemiluminescence using corresponding horserad-
ish peroxidase-conjugated secondary antibodies and
enhanced chemiluminescence detection reagents (GE
Healthcare, Uppsala, Sweden), and then digitized using
the LAS 3000 image analyzer (Fujifilm, Tokyo, Japan).
For secretome samples, equivalent loadings were veri-
fied by Ponceau Red (Sigma) staining after transference
(data not shown). Quantitative changes in band inten-
sities were evaluated using ImageQuant 5.2 software
(GE Healthcare).
Immunohistochemical analysis
Cartilage shavings from three healthy donors different
from those selected for the proteomics strategy were
cut into 6 mm discs using a sterile biopsy punch, and
one disc/well was placed into 96-well plates containing
200 µl serum-free DMEM. Plates were incubated for
48 hours with 200 µg/ml CS in presence of IL-1b
(5 ng/ml). Frozen samples were then cut at 4 μm with
a cryostat (Leica Microsystems, Barcelona, Spain) for
immunohistochemical analysis. Sections were incu-
bated with primary antibody to detect the presence of
TSP1 (1:50; Santa Cruz Biotechnology, Heidelberg,
Germany). The peroxidase/DAB ChemMate™ DAKO
EnVision™ detection kit (Dako, Barcelona, Spain) was
used to determine antigen-antibody interactions. Nega-
tive staining controls were achieved by omitting the
primary mAb. Samples were visualized using an optical
microscope.
Statistical analysis
Each experiment was repeated at least three times. The
statistical significance of the differences between mean
values was determined using a two-tailed t-test, consider-
ing P ≤ 0.05 significant. In the proteomic analysis, normal-
ization tools and the statistical package from Protein Pilot
software were employed (ABSciex). We considered statisti-
cally significant only those changes with P ≤ 0.05 and a
ratio ≥1.2 (or ≤0.83). Where appropriate, results are
expressed as the mean ± standard error.
Results and discussion
Most CS exists as the sugar chains of aggrecan in the
cartilage, and its high water-retaining capacity ensures
proper cartilage hydration [17]. However, several data in
the literature reveal that the mechanism of action of CS
is not limited to the fact that it is part of the aggrecan;
in vivo studies in animal models and in vitro studies
with human and animal articular cells suggest that the
effects of CS result from a combination of numerous
factors [18]. We have performed a gel-free quantitative
proteomics experiment for the secretome analysis (cell-
conditioned media) of HACs treated with bovine CS
(95% purity) in the presence of IL-1b. Although HAC
supernatants lack the complexity of the intact cartilage
ECM, chondrocyte secretome may represent an attrac-
tive subproteome for understanding the chondroprotec-
tive action of CS [19,20].
Secretome profiling of IL-1b and CS-treated HACs
Given the key role of chondrocytes in ECM synthesis
and turnover, and also the importance of these mechan-
isms for tissue maintenance (which are disturbed in OA
and other joint diseases), we examined the effect of CS
in the subset of proteins secreted by chondrocytes
(secretome) in an inflammatory environment (IL-1b).
Inflammatory molecules, such as proinflammatory cyto-
kines, are critical mediators of the disturbed metabolism
and enhance the catabolism of joint tissue involved in
OA pathophysiology [21]. For this purpose, supernatants
from IL-1b-stimulated chondrocytes, with or without CS
treatment, were collected after 48 hours of incubation
and were analyzed. Owing to the low complexity of the
secretome samples, we carried out a monodimensional
approach: we combined equal amounts of proteins from
the experimental conditions to be compared (treated or
untreated with CS, both in the presence of the cyto-
kine), and then these samples were digested in solution
with trypsin. The correspondent tryptic peptides were
separated by LC and the peptides were subsequently
eluted and subjected to mass spectrometry analysis
(MALDI-MS/MS).
This procedure resulted in the identification of 75
proteins present in the culture media of IL-1b-treated
cells with statistical confidence (73 with Protein Pilot
score ≥2). Some of them had not been previously
reported to be secreted by chondrocytes [12], but they
were found in serum [22] and/or synovial fluid [23] of
OA patients and thus possess putative biomarker value.
A complete list of these proteins is shown in Table 1.
The majority of the identified secreted proteins were
cartilage ECM proteins, or proteins with well-established
matrix functions. Furthermore, several mediators of the
inflammatory response were detected. The molecular
Calamia et al. Arthritis Research & Therapy 2012, 14:R202
http://arthritis-research.com/content/14/5/R202
Page 4 of 12
Table 1 Proteins identified in the secretome of IL-1b-stimulated chondrocytes with or without CS treatment
Symbol Score Peptides
(95%)
Covariance
(%)
Accession
numbera
Name Function OA
serum
[22]
OA synovial
fluid [23]
MMP2 20.24 17 36.4 [P08253] 72 kDa type IV collagenase Angiogenesis/collagen
degradation
x
A1AT 2 2 6 [P01009] Alpha-1-antitrypsin Inhibitor of serine proteases
ANXA2 2 1 36 [P07355] Annexin A2 Heat-stress response
B2MG 4 3 26.9 [P61769] Beta-2-microglobulin Immunity x
PGS1 4.03 3 13.9 [P21810] Biglycan Collagen fiber assembly/ECM
component
CATB 3.06 2 15.3 [P07858] Cathepsin B Thiol protease
CCL2 6 4 38.4 [P13500] C-C motif chemokine 2b Inflammatory response
CCL8 4 2 38.4 [P80075] C-C motif chemokine 8b Inflammatory response
CH3L1 63.26 96 82 [P36222] Chitinase-3-like protein 1 ECM component x
CH3L2 2 2 17.7 [Q15782] Chitinase-3-like protein 2b ECM component
CLUS 10.09 9 43.2 [P10909] Clusterin Immunity x x
CCD80 2 1 23.3 [Q76M96] Coiled-coil domain-containing
protein 80
Cell adhesion and matrix
assembly
CO3A1 2.02 1 14.3 [P02461] Collagen alpha-1(III) chain ECM component
CO6A1 4.16 4 28.5 [P12109] Collagen alpha-1(VI) chain ECM component
COCA1 17.35 10 21.1 [Q99715] Collagen alpha-1(XII) chain ECM component
CO1A2 27.65 25 55.2 [P08123] Collagen alpha-2(I) chain ECM component
C1R 8.13 7 31.5 [P00736] Complement C1r subcomponent Immunity x x
C1S 10.6 9 27.3 [P09871] Complement C1s
subcomponent
Immunity x x
CO3 13.4 7 26.4 [P01024] Complement C3 Immunity x
CFAB 8.29 6 17.2 [P00751] Complement factor B Immunity x x
CXCL3 4.01 4 69.2 [P19876] C-X-C motif chemokine 3b inflammatory response
CXCL5 2 1 20.2 [P42830] C-X-C motif chemokine 5b Inflammatory response
CXCL6 4.13 5 38.6 [P80162] C-X-C motif chemokine 6b Inflammatory response
CYTC 4 3 67.1 [P01034] Cystatin-C Inhibitor of cysteine
proteinases
x
PGS2 23.72 22 56 [P07585] Decorin ECM component
DESP 2 1 24.8 [P15924] Desmoplakinb Cell junction x
FBLN3 15.7 12 31.2 [Q12805] EGF-containing fibulin-like
extracellular matrix protein 1
Negative regulator of
chondrocyte differentiation
x x
FINC 152.34 150 58.9 [P02751] Fibronectin ECM component x x
FBLN1 2 1 11.2 [P23142] Fibulin-1 Cell adhesion/ECM
organization
x
FSTL1 2.1 2 16.2 [Q12841] Follistatin-related protein 1 Cell proliferation and
differentiation
GDN 24.73 23 54.5 [P07093] Glia-derived nexin Serine protease inhibitor
GROA 4 5 54.2 [P09341] Growth-regulated alpha protein Inflammatory response
IBP3 12.02 12 57.7 [P17936] Insulin-like growth factor-
binding protein 3
Cell proliferation and
differentiation
x
IBP4 3.36 3 37.6 [P22692] Insulin-like growth factor-
binding protein 4
Cell proliferation and
differentiation
IBP5 4.03 2 55.5 [P24593] Insulin-like growth factor-
binding protein 5
Cell proliferation and
differentiation
IBP6 3.85 3 43.8 [P24592] Insulin-like growth factor-
binding protein 6
Cell proliferation and
differentiation
x
IBP7 2.15 3 29.1 [Q16270] Insulin-like growth factor-
binding protein 7
Cell proliferation and
differentiation
IL6 16 16 42 [P05231] IL-6 Inflammatory response
IL8 4.24 6 57.6 [P10145] IL-8 Inflammatory response
MMP1 35.12 38 50.1 [P03956] Interstitial collagenase Collagen degradation
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function of the identified proteins was categorized by
GeneOntology and is shown in Figure 1. The most
abundant proteins identified in the samples (in terms of
Protein Pilot hits, see Table 1) included well-known car-
tilage-related proteins, namely fibronectin (FN1) and
chitinase-3-like protein 1 (CHI3L1), as well as ECM
degradative enzymes, such as stromelysin-1 (MMP3)
and interstitial collagenase (MMP1).
CS-mediated changes in the chondrocyte secretome
By these means we were able to relatively quantify all
the identified proteins with statistical significance. To
Table 1 Proteins identified in the secretome of IL-1b?β?-stimulated chondrocytes with or without CS treatment
(Continued)
K1C10 60.82 36 66.8 [P13645] Keratin, type I cytoskeletal 10 Intermediate filament x x
K1C14 11.36 7 44.9 [P02533] Keratin, type I cytoskeletal 14b Intermediate filament
K1C16 15.45 8 48 [P08779] Keratin, type I cytoskeletal 16b Intermediate filament
K1C9 30.98 19 60.2 [P35527] Keratin, type I cytoskeletal 9 Intermediate filament x x
K2C1 70.89 41 69.6 [P04264] Keratin, type II cytoskeletal 1 Intermediate filament x x
K22E 43.26 22 69.2 [P35908] Keratin, type II cytoskeletal 2
epidermal
Intermediate filament x x
K2C6B 20.77 11 53.9 [P04259] Keratin, type II cytoskeletal 6Bb Intermediate filament x
MFGM 6.01 4 20.9 [Q08431] Lactadherin Angiogenesis
LUM 28.15 30 60.7 [P51884] Lumican ECM component x x
CSF1 4.01 2 17.3 [P09603] Macrophage colony-stimulating
factor 1b
Inflammatory response
TIMP1 17.8 16 57.5 [P01033] Metalloproteinase inhibitor 1 Metalloprotease inhibitor x
TIMP2 4 3 32.7 [P16035] Metalloproteinase inhibitor 2 Metalloprotease inhibitor
PTX3 2.02 2 14.4 [P26022] Pentraxin-related protein PTX3 Inflammatory response
PLTP 5.8 4 31 [P55058] Phospholipid transfer protein Lipid transport x x
IC1 4 2 18.8 [P05155] Plasma protease C1 inhibitor Immunity x x
POTEF 2.03 1 27.6 [A5A3E0] POTE ankyrin domain family
member Fb
Unknown
SAP 2 1 5 [P07602] Proactivator polypeptideb Lipid metabolism
PCOC1 5.93 4 19.8 [Q15113] Procollagen C-endopeptidase
enhancer 1
Collagen metabolism x
S10A8 1.54 1 35.5 [P05109] Protein S100-A8b Inflammatory response x
S10A9 4 2 34.2 [P06702] Protein S100-A9b Inflammatory response x
PRG4 3.7 3 21.9 [Q92954] Proteoglycan 4b ECM component x x
TRY6 4 2 15.4 [Q8NHM4] Putative trypsin-6b Serine protease
NPT2C 2 1 10.9 [Q8N130] Sodium-dependent phosphate
transport protein 2Cb
Ion transport
SPRC 2 2 7.3 [P09486] SPARC Cell proliferation and
differentiation
x
MMP3 48.64 47 71.9 [P08254] Stromelysin-1 Collagen degradation x
QSOX1 4.87 4 16.3 [O00391] Sulfhydryl oxidase 1 Cell redox homeostasis x
SDC4 2 1 13.6 [P31431] Syndecan-4 ECM component
TARSH 8.86 9 27.4 [Q7Z7G0] Target of Nesh-SH3 Cell proliferation and
differentiation
x
TENA 13.36 8 22.5 [P24821] Tenascin Cell adhesion/ECM
organization
TETN 4 4 34.2 [P05452] Tetranectin Bone mineralization x x
TSP1 2.36 2 18.5 [P07996] Thrombospondin-1 Angiogenesis x
BGH3 2 1 22.6 [Q15582] TGF-beta-induced protein ig-h3 TGF-beta signaling x
TSG6 28.35 30 69.3 [P98066] TNF-inducible gene 6 protein Cell adhesion
VCAM1 2 1 12.2 [P19320] Vascular cell adhesion protein 1 Cell adhesion x
VASN 2 2 14.7 [Q6EMK4] Vasorin TGF-beta signaling x
Proteins identified by SILAC and liquid chromatography-mass spectrometry analysis in the secretome of IL-1b-stimulated chondrocytes with or without
chondroitin sulfate treatment. ECM, extracellular matrix; EGF, epidermal growth factor; TGF, transforming growth factor. aProtein accession number according to
the SwissProt and TrEMBL databases. bProtein not identified in our previous analysis of chondrocyte secretome [12].
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confirm our findings and exclude the possibility of any
quantification differences arising from SILAC labeling
[24], the whole experiment was replicated with treat-
ment conditions crossed over (swapping the labeled
state of the perturbed cells). Finally, among the identi-
fied proteins, 18 presented a significant alteration of
their levels due to the pharmacological treatment (six
increased and 12 decreased), which are listed in Table 2.
We detected the modulation of proteins involved in sev-
eral processes, such as cartilage ECM structural organi-
zation (three proteins, including noncollagenous
proteins and proteoglycans), ECM remodeling (four pro-
teins, including proteases and their inhibitors), immune
response (six proteins) and angiogenesis (two proteins).
Interestingly, we found distinctively in CS-treated cells
a global decrease of immunity-related proteins, degrada-
tive enzymes (such as MMP1, MMP2, and MMP3), and
some ECM structural proteins (such as fibronectin (FN1)
and chitinase-3-like protein 1 (CHI3L1)). Among those
proteins described in our previous work as increased by
IL-1b [12], which were now decreased by CS, we found
FN1 and CHI3L1, two components of normal cartilage
matrix (Figure 2). Synthesis and release of both proteins
and fragments is often increased in cartilage that is
undergoing repair or remodeling, and they have been
investigated as markers of cartilage damage in OA
[25-27]. Interestingly, the release of FN1 and CHI3L2
from chondrocytes was also detected in a previous pro-
teomic analysis from our group, which aimed to evaluate
the differential effect of three distinct CS molecules in
chondrocytes [28]. In that work, the presence of these
proteins in the chondrocyte secretomes was caused by
treatment with a CS of porcine origin, which appeared to
trigger catabolic effects in chondrocytes by increasing
also the abundance of matrix metalloproteinases (MMP1
and MMP3). On the contrary, treatment with bovine CS
(the one employed in the present study) did not have any
effect on the release of these four proteins.
Putative mediators of CS anti-inflammatory and anti-
catabolic effects
We also performed a database search, using STRING
software, to visualize protein interactions on the set of
CS-modulated proteins and further elucidate its effect
on chondrocytes (Figure 3). The role of CS in counter-
acting the IL-1b-mediated increase of some proteins was
Figure 1 Bioinformatic analysis of identified and differentially abundant proteins. Bioinformatic analysis of (A) identified and (B)
differentially abundant proteins according to the Gene Ontology database. The functional distribution graph reveals anti-inflammatory and
immunomodulatory properties of chondroitin sulfate, apart from its role in extracellular matrix (ECM) structure.
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Table 2 Extracellular proteins modulated by chondroitin sulfate treatment in IL-1b-stimulated chondrocytes
Accession numbera Name Symbol Ratiob P value Error factorc
[P00751] Complement factor B CFAB 0.5566 0.0064 1.397
[Q08431] Lactadherin MFGM 0.597 0.0151 1.3855
[Q7Z7G0] Target of Nesh-SH3 TARSH 0.7017 0.006 1.2209
[P09871] Complement C1s subcomponent C1S 0.7085 0.0007 1.1398
[P01024] Complement C3 CO3 0.7241 0.0023 1.1999
[P02751] Fibronectin FINC 0.7321 0.0006 1.1891
[P03956] Interstitial collagenase MMP1 0.7113 0 1.0977
[P00736] Complement C1r subcomponent C1R 0.7734 0.0071 1.1755
[P08253] 72 kDa type IV collagenase MMP2 0.7759 0.0001 1.0999
[P36222] Chitinase-3-like protein 1 CH3L1 0.8088 0.0216 1.4096
[P10909] Clusterin CLUS 0.8224 0.05 1.2162
[P08254] Stromelysin-1 MMP3 0.8256 0.0086 1.1378
[P07093] Glia-derived nexin GDN 1.2894 0.0031 1.1664
[O00391] Sulfhydryl oxidase 1 QSOX1 1.3064 0.0382 1.2709
[Q92954] Proteoglycan 4 PRG4 1.4393 0.05 1.445
[P98066] TNF-inducible gene 6 protein TSG6 1.7773 0.0007 1.3371
[P61769] Beta-2-microglobulin B2MG 2.1652 0.0125 1.4553
[P07996] Thrombospondin-1 TSP1 89.1678 0 >2
Extracellular proteins identified by SILAC and liquid chromatography-mass spectrometry analysis as modulated by CS treatment in IL-1b-stimulated chondrocytes.
aProtein accession number according to the SwissProt and TrEMBL databases. bAverage SILAC ratios (n = 3) that represent the relative protein abundance in CS-
treated versus untreated cells, calculated by Protein Pilot 3.0 software (ABSciex). P ≤ 0.05 was accepted. cError factor of the quantification (measure of the error in
the average quantification ratio as calculated by Protein Pilot 3.0 software).
Figure 2 Role of chondroitin sulfate in counteracting IL-1b-mediated increase of proteins. Role of chondroitin sulfate (CS) in counteracting
IL-1b-mediated increase of proteins related to extracellular matrix (ECM) remodeling, catabolism and inflammation. Graphics show the
quantitative modulation caused by CS on this group of proteins (ratio IL+CS/IL, light-gray bars) detected in the present study, and compare
these changes with those attributable to IL-1b treatment (ratio IL/BASAL, dark-gray bars) that were found previously [12]. Protein abbreviations
are defined in Table 2.
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also detected for three degradative enzymes and three
members of the complement pathway (Figure 2 and
Table 2). Recently, a central role for the inflammatory
complement system in the pathogenesis of OA has been
identified [29]. Expression and activation of complement
is abnormally high in human osteoarthritic joints. We
show in this study how CS could reduce inflammation
directly by decreasing the presence of several comple-
ment components (CFAB, CLUS, CO3, C1S and C1R),
and also indirectly by increasing proteins such as TSG6.
This protein plays a crucial role in ECM formation,
inflammatory cell migration and cell proliferation. TSG6
is also a key component of a negative feedback loop
operating through the protease network that reduces
matrix degradation during the OA process [30]. The
mechanism driven by TSG6 leads to a decrease in pro-
matrix metalloproteinase activation, which might protect
cartilage from extensive degradation even in the
Figure 3 Protein-protein interaction network of chondroitin sulfate effects. The STRING database was searched for protein interaction
analyses in order to elucidate the effect of chondroitin sulfate on cartilage extracellular matrix (ECM) proteins. As shown, most of the altered
proteins interact with each other to constitute a large network. These proteins are involved in several processes, but essentially belong to
immune response, inflammation and ECM remodeling pathways.
Figure 4 Chondroitin sulfate-dependent increase of TNFa-induced protein and correlation with the decrease in matrix
metalloproteinase activation. The chondroitin sulfate (CS)-dependent increase of TNFa-induced protein (TSG6 or TNFAIP6), and its correlation
with the decrease in matrix metalloproteinase activation. Overexpression values of TSG6 were determined by (A) real-time PCR and (B) western
blot analysis of IL-1b-stimulated human articular chondrocyte secretomes as described in Materials and methods. The CS-mediated decrease of
MMP1 and MMP3 activation was confirmed by western blot analysis (B). Each condition was tested in duplicate. Results are expressed as the
mean ± standard error of the mean of three independent experiments. Representative images of the western blot assays are shown. *P < 0.05,
CS-treated group was significantly different from IL-1b-stimulated group.
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presence of acute inflammation (represented in our case
by a high level of IL-1b). Western blot analyses were
performed to confirm the detected increase of TSG6
caused by CS treatment. As shown in Figure 4, CS
increased the amount of TSG6 secreted by chondro-
cytes, and this increase correlates with a decline in
MMP1 and MMP3 levels. These results point to the
increase of TSG6 as a putative mediator of the reduc-
tion in pro-matrix metalloproteinase activation, suggest-
ing an important role of this mechanism for the anti-
catabolic effect of CS.
Modulation of thrombospondin-1 by CS
A remarkable increase of TSP1, an angiogenesis inhibitor,
was detected as a consequence of the CS treatment and
counteracting the effect of IL-1b. This result is consistent
with our previously observed increase of TSP1 protein dri-
ven by CS in the absence of IL-1b stimulation, although in
osteoarthritic chondrocytes [28]. TSP1 overexpression
reduces inflammation and neovascularization in the OA
joint [31]. In our previous study on IL-1b-stimulated
chondrocytes, TSP1 presented a ratio of zero [12], indicat-
ing a cytokine-dependent dramatic decrease of its release
Figure 5 Thrombospondin-1 (TSP1 or THBS1) is increased by chondroitin sulfate. Overexpression values of thrombospondin-1(TSP1) were
determined by (A) real-time PCR and (B) western blot (WB) analysis of both IL-1b-stimulated and unstimulated human articular chondrocytes,
and by (C) immunohistochemical analysis of cartilage shavings as described in Materials and methods. Each condition was tested in duplicate.
Results are expressed as the mean ± standard error of the mean of three independent experiments. Representative images of western blot and
immunohistochemical assays are shown. *P < 0.05, CS-treated group was significantly different from IL-1b-stimulated group. CS, chondroitin
sulfate; CTL, control.
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from these cells. IL-1b is a well-recognized angiogenic fac-
tor, so the possibility that an increased concentration of
IL-1b in OA synovial fluid may reduce the TSP1 expres-
sion in severe stages of OA cannot be excluded. The selec-
tive inhibition of angiogenesis - also confirmed by the
decrease of lactadherin, a protein that promotes vascular
endothelial growth factor-dependent neovascularization
[32] - demonstrates a novel mechanism of action of CS
according to recent results obtained in synoviocytes [33].
The data obtained in the SILAC analysis need to be
validated for differences in protein expression profiles
before the biological roles of the modulated proteins are
extensively studied. We therefore performed additional
studies in order to verify the altered abundance of TSP1
in CS-treated chondrocytes. Interestingly, TSP1 is a mul-
tifunctional adhesive glycoprotein present in articular
cartilage and synthesized by articular chondrocytes [34],
whose gene transfer suppresses the disease progression
of experimental OA [31]. The inhibitory effect of TSP-1
on angiogenesis has been largely described [35]. Owing
to the pivotal role of angiogenesis in OA physiopathology
[36], we decided to verify TSP1 gene expression level in
CS-treated chondrocytes stimulated with IL-1b by real
time-PCR analysis, and also in cells without cytokine sti-
mulation. As shown in Figure 5A, CS upregulates TSP1
already in the absence of IL-1b. When the cytokine is
present, CS is capable of counteracting its suppressive
effect on TSP1 in chondrocytes. Furthermore, TSP1 pro-
tein levels were also evaluated in chondrocyte condi-
tioned media (secretome) and cellular extracts
(proteome) by western blot analyses and in cartilage
explant culture by immunohistochemistry (Figure 5). The
increase of TSP1 protein observed both in cell and tissue
cultures following CS treatment suggests the possible
mechanism through which this drug could exert an anti-
angiogenic action.
Conclusion
Our work provides a comprehensive quantitative analy-
sis of the effects of CS in IL-1b-stimulated chondrocyte
secretome, as well as novel molecular evidence for its
anti-angiogenic, anti-inflammatory, and anti-catabolic
properties. Proteins modulated by this drug are potential
new targets for OA treatment (for example, TSP1).
These findings might provide a rationale for targeting
angiogenesis as a disease-modifying therapy for OA.
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